Grassley Rx Import Bill Offers R&D Tax Incentive To Cooperating Manufacturers
This article was originally published in The Pink Sheet Daily
Executive Summary
The "REMEDIES Act" would increase the research tax credit by 20% to companies that certify they have not directly or indirectly moved to prevent authorized importation. The program is limited to Canada for the first two years; in the third year it expands to include Europe, Japan, Australia and New Zealand.